Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma): lines of therapy Print / save PDF Cancer page → 5 standard-of-care settings across 3 lines and 2 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
Line All comers FRα Advanced, first line 2 · Third line and beyond · 1 Other settings 2 ·
Advanced, first line Subgroup Setting Approach Products and trials Guideline Evidence All comers First line, CD30+ PTCL / ALCL Brentuximab vedotin autologous transplant NCCN · Category 1 (ALCL) ESMO-MCBS · 4 83 All comers First line, other nodal PTCL CHOP autologous transplant consolidation responders clinical trial NCCN · Category 2A 79
Third line and beyond Subgroup Setting Approach Products and trials Guideline Evidence FRα Relapsed/refractory PTCL Pralatrexate belinostat romidepsin CD30 regimens allogeneic HSCT NCCN · Category 2A 83
Other settings Subgroup Setting Approach Products and trials Guideline Evidence All comers Mycosis fungoides / Sézary Skin-directed therapy (topical steroids, phototherapy, radiotherapy beam mogamulizumab CD30 interferon allogeneic HSCT NCCN · Category 1 (mogamulizumab, brentuximab) 83 All comers Extranodal NK/T-cell Asparaginase-based chemotherapy radiotherapy localised PD-1 inhibitors relapse 98
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.